Iowamed spa & injectable regulations

What’s changing for med spas and injectors in Iowa — GLP-1 compounding, scope-of-practice, and enforcement — plus the federal FDA and Federal Register actions that apply in Iowa. Med Spa Radar monitors it all and tells you, in plain language, what changed and what to do.

Latest Iowa changes

Federal changes that apply in Iowa

FDA and Federal Register actions are nationwide — they govern Iowa practices too.

See the full regulatory feed →

What we monitor in Iowa

  • Iowa legislature — bills on injectables, GLP-1s & scope of practice
  • Iowa Board of Nursing — injector scope & delegation
  • Iowa Medical Board — physician supervision & ownership rules
  • Iowa Board of Pharmacy — compounding & 503A/503B
  • U.S. FDA — enforcement, warning letters, recalls, shortages
  • Federal Register — new rules on compounding & aesthetics

Iowa med spa compliance — FAQ

Where do Iowa med spa and injectable regulations come from?
Iowa med spas and injectors are governed by a mix of state and federal authorities — the Iowa legislature, and the state's boards of nursing, medicine, and pharmacy, alongside federal bodies like the FDA and the Federal Register. Med Spa Radar monitors all of them for Iowa and flags what changed in plain language.
Does the FDA's GLP-1 compounding guidance apply in Iowa?
Yes — federal FDA actions on GLP-1 compounding (semaglutide, tirzepatide) apply nationwide, including in Iowa. We track those federal changes alongside any Iowa-specific rules so you see the full picture for your practice.
How do I keep up with Iowa regulatory changes?
Med Spa Radar sends a free weekly Brief on what changed across Iowa, the FDA, and the Federal Register. Members get the exact "what to do" for their states in real time. It's regulatory monitoring, not legal advice.

Never miss a Iowa change

Get the free weekly Brief on what changed across Iowa, the FDA, and the Federal Register. Members get the exact what-to-do, in real time, for their states.

Get the free Brief →

← All states · Regulatory monitoring, not legal advice.